Influenza Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Influenza Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global influenza diagnostics market is on the brink of significant expansion, with worldwide revenue reaching US$ 1.81 billion in 2024 and projected to reach a valuation of US$ 3.06 billion by the end of 2031. This growth is attributed to several key factors and innovations in diagnostic tests for influenza infection.

New Advancements in Diagnostic Tests for Influenza Infection Drive Growth

A range of diagnostic tools, including reverse transcription polymerase chain reaction (RT-PCR), viral cultures, fluorescence assays, serological tests, antigen testing, and rapid molecular assays, are available for influenza detection. Among these, commercial rapid flu diagnostic tests are the most widely used due to their ability to provide results with low to medium sensitivity and high specificity within just 15 minutes.

Molecular diagnostic assays represent a breakthrough in influenza testing, offering high sensitivity and specificity. Reverse transcription polymerase chain reaction (RT-PCR) and nucleic detection techniques have significantly improved the detection of respiratory viruses. Molecular tests utilize nucleic acid

amplification testing (NAT) to identify specific known viruses, surpassing other diagnostic methods in various aspects.

Market Growth Impacted by Labor Shortage and High Testing Costs

Despite these advancements, the influenza diagnostics market faces challenges such as a shortage of skilled personnel and the high costs associated with molecular diagnostic procedures, reagents, and equipment. Developing nations, like India and China, often struggle to afford these expenses, limiting access to advanced diagnostic methods.

Additionally, rapid diagnostic approaches for influenza may have limitations in identifying specific viral subtypes, potentially leading to misinterpretations. To validate negative test results, expensive and time-consuming diagnostic tools are required, even in low influenza activity periods.

Country-wise Insights

U.S. Market Boom Driven by Increasing Prevalence

The United States, experiencing a rising prevalence of influenza, is expected to witness a surge in the adoption of diagnostic kits. Influenza is the most commonly diagnosed condition in the U.S., with a substantial number of cases reported. Key industrial firms like Abbott and Quidel Corporation contribute to market expansion through the development and marketing of new products.

Germany - A Lucrative Market for Innovative Kits

Germany is poised to dominate the regional market for rapid influenza diagnostic tests due to increasing influenza prevalence, supportive government interventions, influential industry leaders, and advanced facilities. The presence of manufacturing facilities and collaborative research efforts further enhance access to influenza testing kits.

Japan's Prominence in Influenza Diagnostics

Japan emerges as a prominent market for rapid influenza diagnostics, driven by a modern healthcare system, favorable legislation, and insurance. The country's expanding market is also associated with research advancements in influenza diagnostics technology, a growing geriatric population, and the demand for rapid disease diagnostics.

Competitive Landscape

Mergers and acquisitions are key growth strategies in the global influenza diagnostics market. Leading organizations are expanding their product lines through strategic partnerships and acquisitions. Key players in the market include:
• Abbott Laboratories
• Endress+Hauser (Analytik Jena AG)
• Becton, Dickinson and Company
• Biocartis
• bioMérieux Inc
• Danaher Corporation (Cepheid)
• F. Hoffmann-La Roche Ltd
• GenMark Diagnostics, Inc.
• Luminex Corporation
• Meridian Bioscience, Inc
• Quidel Corporation
• Thermo Fisher Scientific Inc.
• Hologic

Key Segments Covered in Influenza Diagnostics Industry Research

Test:
• Molecular Diagnostic Test
RT-PCR
LAMP
NASABA
• Traditional Diagnostic Test
Rapid Influenza Detection Test
Serological Assays
Direct Fluorescent Antibody
Viral Culture
H1N1 Influenza A Virus Identification Kits
Immunoassay Kits
Immunofluorescence Antibody Assay

Type of Flu:
• Type A Flu
• Type B Flu
• Type C Flu

End User:
• Hospitals
• Diagnostic Laboratories
• Research & Academic Institute
• Contract Research Organization (CRO’s)

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.